首个非处方口服避孕药获得批准。

IF 1.8 4区医学 Q2 NURSING

Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing Pub Date : 2024-09-01 DOI:10.1016/j.jogn.2024.08.001

Summer Sherburne Hawkins

{"title":"首个非处方口服避孕药获得批准。","authors":"Summer Sherburne Hawkins","doi":"10.1016/j.jogn.2024.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.</p></div>","PeriodicalId":54903,"journal":{"name":"Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing","volume":"53 5","pages":"Pages 464-476"},"PeriodicalIF":1.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Approval of the First Nonprescription Oral Contraceptive Pill\",\"authors\":\"Summer Sherburne Hawkins\",\"doi\":\"10.1016/j.jogn.2024.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.</p></div>\",\"PeriodicalId\":54903,\"journal\":{\"name\":\"Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing\",\"volume\":\"53 5\",\"pages\":\"Pages 464-476\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0884217524002612\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0884217524002612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

摘要

2023 年 7 月，美国食品和药物管理局批准了 Opill（诺孕酮 0.075 毫克），这是一种无需处方即可使用的纯孕激素避孕药片。虽然只含孕激素的避孕药早在 1973 年就已获批，但第一种口服避孕药在柜台销售却用了 50 年的时间。在本专栏中，我将回顾有关获得口服避孕药的障碍、非处方药孕激素避孕药的疗效、偏好和支持、成本以及对医疗保险的政策影响等方面的证据。最后，我将介绍专业组织对非处方药荷尔蒙避孕药的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Approval of the First Nonprescription Oral Contraceptive Pill

In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Jognn-Journal of Obstetric Gynecologic and Neonatal Nursing 医学-妇产科学

CiteScore

3.20

自引率

5.60%

发文量

审稿时长

43 days

期刊介绍： JOGNN is a premier resource for health care professionals committed to clinical scholarship that advances the health care of women and newborns. With a focus on nursing practice, JOGNN addresses the latest research, practice issues, policies, opinions, and trends in the care of women, childbearing families, and newborns. This peer-reviewed scientific and technical journal is highly respected for groundbreaking articles on important - and sometimes controversial - issues. Articles published in JOGNN emphasize research evidence and clinical practice, building both science and clinical applications. JOGNN seeks clinical, policy and research manuscripts on the evidence supporting current best practice as well as developing or emerging practice trends. A balance of quantitative and qualitative research with an emphasis on biobehavioral outcome studies and intervention trials is desired. Manuscripts are welcomed on all subjects focused on the care of women, childbearing families, and newborns.